OCTA and Glaucoma Progression in the Non-Human Primate
OCTA and Glaucoma Progression in the Non-Human Primate
批准号:
10649710
负责人:
Nimesh Bhikhu Patel
金额:
$55.5万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-08-01 至 2026-05-31
关键词:
3-DimensionalAgeAnatomyAngiographyAnimalsAutopsyBasement membraneBlindnessBlood VesselsBlood capillariesBlood flowCannulationsCell DensityClinicalDataData SetDiseaseDisease ProgressionEndothelial CellsEuthanasiaExperimental ModelsExposure toEyeEye diseasesFaceGlaucomaHealthHistologicHumanImageImmunohistochemistryIndividualIndividual DifferencesLeftMeasuresMetabolicMethodsModelingMonitorNatureOptic DiskOptical Coherence TomographyPapillaryPathologicPathologyPatientsPerfusionPericytesPerimetryPhysiologic Intraocular PressurePopulationPrevalenceProcessPropertyRadialRegulationRetinaRetinal Ganglion CellsRiskRisk FactorsScanningScanning Electron MicroscopyStructureTechnologyTestingThickThinnessTimeTissuesTransmission Electron MicroscopyVascular blood supplyVisionadaptive optics scanning laser ophthalmoscopyanterior chambercomparativedensitydisorder riskexperimental analysisexperimental studyhigh riskhuman subjectin vivoinnovationmaculaneuralnonhuman primateoptic nerve disorderperfusion imagingpressurereconstructionregional differenceresponseretinal damageretinal nerve fiber layervascular factor
中文摘要
描述
青光眼是一组导致视网膜神经节细胞(RGC)的病理性损失和不可逆的视网膜损害的疾病。
视力丧失眼内压(IOP)升高是青光眼的主要危险因素,但一些患有青光眼的个体
高压力不会导致疾病,而低压力的人则会失明。同样,在
在非人灵长类动物实验性青光眼模型中,显示具有相似IOP曲线的动物具有
视网膜神经纤维层(RNFL)厚度丢失的程度和速率有显著差异。临床和
实验模型表明,除了眼压外,青光眼还需要考虑其他因素
进展我们假设疾病进展的变异性可以通过血管因素来解释。的
视网膜是人体内代谢最多的组织之一,目前尚不清楚血管相对较低的眼睛是否会发生视网膜病变。
体积,或显示灌注随IOP变化而变化较大的眼睛具有更大的病理风险。
此外,虽然患有视神经病变的眼睛血管密度降低,但仍不清楚是否存在血管密度降低。
是在RGC丧失之前的视网膜血管系统的变化。光学相干断层扫描血管造影(OCTA)
是一种用于三维血管灌注成像的非侵入性方法。然而,对OCTA成像的分析
在脉管系统中,基于平板投影,其中失去了组织的三维性质。此外,OCTA
血管灌注通常被认为是静态测量,但血管流速具有时间特性。为
在这个项目中,我们优化了OCTA扫描,以量化血管体积和血管体积密度,并使用
序列和配准扫描,OCTA时间变异性。在非人类灵长类实验性青光眼中,
模型,我们将确定; 1。如果疾病进展率与基线全球和地区指标相关
血管体积/体积密度和局部OCTA时间变异性,2。如果有血管容量的损失
前视网膜内层厚度,3.如果结构和功能变化的速度与
其中血管灌注随IOP激发而改变,以及4.利用死后组织,定义血管解剖
(周细胞覆盖率、内皮细胞密度、毛细血管基底膜厚度/完整性)
疾病眼睛和与体内OCTA测量的相关性。成功完成这些目标将确定,
使用OCTA量化的血管测量可用于确定病理风险和青光眼发生率
进展
英文摘要
DESCRIPTION
Glaucoma is a group of diseases that results in a pathological loss of retinal ganglion cells (RGC) and irreversible
vision loss. Increased intraocular pressure (IOP) is a major risk factor for glaucoma, but some individuals with
elevated pressures never develop disease, and others with low pressures progress to blindness. Similarly, in the
non-human primate experimental glaucoma model, animals with similar IOP profiles are shown to have
significant differences in the extent and rate of retinal nerve fiber layer (RNFL) thickness loss. Both clinical and
experimental models suggest that in addition to IOP, other factors need to be considered for glaucoma
progression. We hypothesize the variability in disease progression can be explained by vascular factors. The
retina is one of the most metabolic tissues in the body, and it is unknown if eyes with relatively lower vascular
volume, or eyes that show greater change in perfusion with changes in IOP are at greater risk of pathology.
Furthermore, although eyes with optic neuropathy have reduced vascular density, it remains unknown if there
are changes in retinal vasculature that precede RGC loss. Optical coherence tomography angiography (OCTA)
is a non-invasive method for three-dimensional vascular perfusion imaging. However, analysis of OCTA imaged
vasculature is based on slab projections, where the three-dimensional nature of tissue is lost. In addition, OCTA
vascular perfusion is often considered a static measure, but vascular flow velocity has temporal properties. For
this project, we have optimized OCTA scans to quantify vascular volume and vascular volume density, and using
sequential and registered scans, OCTA temporal variability. In the non-human primate experimental glaucoma
model, we will determine; 1. if the rate of disease progression is related to baseline global and regional measures
of vascular volume / volume density and regional OCTA temporal variability, 2. if there is loss of vascular volume
prior to inner retinal thickness, 3. if the rate of structural and functional changes are is related to the extent to
which vascular perfusion changes with IOP challenge, and 4. using post-mortem tissue, define vascular anatomy
(pericyte coverage, endothelial cell density, capillary basement membrane thickness/integrity) in healthy and
disease eyes and association with in vivo OCTA measures. Successful completion of these aims will establish if
vascular measures as quantified using OCTA can be used to determine risk of pathology, and rate of glaucoma
progression.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
OCTA and Glaucoma Progression in the Non-Human Primate
-
批准号:10415689
-
项目类别:
-
资助金额:$53.76万
-
财政年份:2022
-
负责人:Nimesh Bhikhu Patel
-
依托单位:
Relating Structure to Function in Optic Neuropathies
-
批准号:10334429
-
项目类别:
-
资助金额:$37.1万
-
财政年份:2019
-
负责人:Nimesh Bhikhu Patel
-
依托单位:
Relating Structure to Function in Optic Neuropathies
-
批准号:10547776
-
项目类别:
-
资助金额:$38.25万
-
财政年份:2019
-
负责人:Nimesh Bhikhu Patel
-
依托单位:
Retinal Nerve Fiber Layer Area in Aging and Glaucoma
-
批准号:8165940
-
项目类别:
-
资助金额:$20.66万
-
财政年份:2011
-
负责人:Nimesh Bhikhu Patel
-
依托单位:
Retinal Nerve Fiber Layer Area in Aging and Glaucoma
-
批准号:8306705
-
项目类别:
-
资助金额:$21.01万
-
财政年份:2011
-
负责人:Nimesh Bhikhu Patel
-
依托单位:
Retinal Nerve Fiber Layer Area in Aging and Glaucoma
-
批准号:8531255
-
项目类别:
-
资助金额:$21.01万
-
财政年份:2011
-
负责人:Nimesh Bhikhu Patel
-
依托单位:
Retinal Nerve Fiber Layer Area in Aging and Glaucoma
-
批准号:8720774
-
项目类别:
-
资助金额:$21.01万
-
财政年份:2011
-
负责人:Nimesh Bhikhu Patel
-
依托单位:
Biological Imaging Module
-
批准号:10724942
-
项目类别:
-
资助金额:$11.17万
-
财政年份:1997
-
负责人:Nimesh Bhikhu Patel
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: